Company Overview and News

 
Nearmap’s shares continue to rise as contract value hits record high

2018-03-02 proactiveinvestors.com.au
Nearmap Ltd’s (ASX:NEA) share price is up 59% year to date at $0.945, as annualised contract value grew 31% to $54.2 million for the six months ended 31 December 2017.

 
Soil Sub Technologies Ltd raises $5M, shifts to cloud mapping technology

2016-05-31 proactiveinvestors.com.au
Soil Sub Technologies Ltd (ASX:SOI) has successfully closed a $5 million capital raising and will soon be relisted as Pointerra Ltd as part of a reverse takeover. The company had offered investors 166.6 million shares at an issue price of $0.03 each to raise $5 million, with RM Corporate Finance underwriting the offer up to $3.6 million. Pointerra is an emerging cloud based technology company building a Data as a Service (DaaS) solution for mapping the world in 3D through the processing, managing and sharing of cloud data sets.

 
Appendix 3B

2016-05-10 asx.com.au

 
 
Lapse of Options

2016-04-11 asx.com.au

 
Lapse of Options

2016-04-01 asx.com.au

 
Appendix 3B

2016-03-29 asx.com.au

 
 
Presentation

2016-03-18 asx.com.au

 
Results of general meeting

2016-03-18 asx.com.au

 
Appointment of Chairman

2016-03-18 asx.com.au

 
Lapse of Options

2016-02-22 asx.com.au

 

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...